Suche
Mein Konto
New analysis finds significant differences in treatment of familial hypercholesterolemia
The Family Heart Foundation, a leading research and advocacy organization, shared results of an analysis of its large U.S. Family Heart DatabaseTM that shows significant disparities in the treatment of familial hypercholesterolemia (FH) exist among racial groups and by income and education levels. A real-world data analysis of more than 300 million people showed that people with FH who are white, male, and have higher income or education are more likely to be prescribed appropriate lipid-lowering therapy, leaving many others undertreated. The results will be presented in a poster at the American Heart Association scientific meetings on November 7 in Chicago...
New analysis finds significant differences in treatment of familial hypercholesterolemia
The Family Heart Foundation, a leading research and advocacy organization, shared results of an analysis of its large U.S. Family Heart DatabaseTM that shows significant disparities in the treatment of familial hypercholesterolemia (FH) exist among racial groups and by income and education levels. A real-world data analysis of more than 300 million people showed that people with FH who are white, male, and have higher income or education are more likely to be prescribed appropriate lipid-lowering therapy, leaving many others undertreated. The findings will be presented in a poster titled “Using Healthcare Claims Data and Machine Learning to Identify Health Disparities for Individuals with Diagnosed and Undiagnosed Familial Hypercholesterolemia” at the American Heart Association Scientific Sessions on November 7 in Chicago.
Individuals with FH are at very high risk of premature cardiovascular events and require early and intensive lipid-lowering therapy, but most individuals receive far from adequate care. These results highlight the significant unmet need to improve equity and provide all individuals with FH an opportunity to reduce cardiovascular risk.”
Mary P. McGowan, MD, chief medical officer, Family Heart Foundation, and co-author of the study
Genetics & Genomics eBook
Compilation of the top interviews, articles and news from the last year. Download a free copy
The observational study included patients diagnosed with FH and those with probable FH but not yet diagnosed (probable FH). Probable FH patients were identified by the Family Heart Foundation's validated FIND-FH® machine learning model. Filled prescriptions for statins, ezetimibe, and PCSK9i, as well as age, education, income, race/ethnicity, and gender were assessed. Among more than 77 million individuals analyzed in this dataset, 280,426 had a diagnosis of FH (51% female, 79.5% white, 11.8% black, and 8.7% Hispanic) and 899,027 had probable FH (48% female, 78.7% white, 12.9% black, and 8.5% Hispanic).
Key findings within both diagnosed and probable FH groups:
- Im Vergleich zu Schwarzen erhielten Weiße mit 6 bis 30 % höherer Wahrscheinlichkeit Ezetimib, PCSK9i oder die Kombination aus Statin, Ezetimib und PCSK9i.
- Männer erhielten im Vergleich zu Frauen mit 46 bis 48 % höherer Wahrscheinlichkeit hochintensive Statine.
- Bei Personen mit einem Haushaltseinkommen von 100.000 USD und mehr war die Wahrscheinlichkeit, Ezetimib, PCSK9i oder die Kombination aus Statin, Ezetimib und PCSK9i zu erhalten, um 30 bis 50 % höher als bei Personen mit einem Haushaltseinkommen von weniger als 49.000 USD.
- Bei Patienten mit diagnostizierter FH mit Hochschulabschluss war die Wahrscheinlichkeit, dass sie die Kombination aus Statin, Ezetimib und PCSK9i erhielten, um 51 % höher als bei Patienten mit einer höheren Schulbildung oder weniger.
Data analysis was conducted on the Family Heart Database, which includes diagnostic, procedural and prescription data from claims and/or laboratory information for more than 300 million individuals in the United States
Source:
.